Mika Shapiro
YOU?
Author Swipe
View article: Novel immunotherapy for multiple solid cancers using an Anti-HVEM blocking monoclonal antibody
Novel immunotherapy for multiple solid cancers using an Anti-HVEM blocking monoclonal antibody Open
INTRODUCTION Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their efficacy remains limited. Therefore, there is a clear need for new anti-tumor agents. HVEM (Herpes Virus Entry Mediator) plays a regulatory ro…
View article: Spatial organization and early signaling of the B-cell receptor in CLL
Spatial organization and early signaling of the B-cell receptor in CLL Open
Most chronic lymphocytic leukemia (CLL) clones express B-cell receptors (BcR) of both IgM/IgD isotypes; however, 5%–10% of CLL cases express isotype-switched immunoglobulin G (IgG). The early signaling and spatial patterning of the various…
View article: CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia
CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia Open
Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and progressive accumulation of mature B lymphocytes in the peripheral blood, lymphoid tissues, and bone marrow. CLL is characterized by profound immune defects le…
View article: MALT1 INHIBITION USING THE SMALL MOLECULE INHIBITOR MI‐2 EFFICIENTLY INDUCES APOPTOSIS IN CLL CELLS
MALT1 INHIBITION USING THE SMALL MOLECULE INHIBITOR MI‐2 EFFICIENTLY INDUCES APOPTOSIS IN CLL CELLS Open
The NFκB pathway plays a crucial role in cancer cell survival, proliferation and acquisition of resistance to therapy. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is an intermediary protein paracaspase import…
View article: Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia Open
A novel therapeutic approach in cancer, attempting to stimulate host anti-tumor immunity, involves blocking of immune checkpoints. Lymphocyte activation gene 3 (LAG3) is an immune checkpoint receptor expressed on activated/exhausted T cell…
View article: SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course
SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course Open
SLP76 is ectopically expressed in chronic lymphocytic leukemia cells where it plays a role in B-cell receptor signaling.